However, CRC patients with KRAS [94] and NRAS [95] gene mutations, possibly due to mutations in downstream genes such as BRAF [96], have been demonstrated to be insensitive to treatment with EGFR inhibitor. Here, NRAS is linked to colorectal carcinoma.